Submacular Injection of Ranibizumab As a New Surgical Treatment for Refractory Diabetic Macular Edema

Overview

Journal J Ophthalmol

Publisher Wiley

Specialty Ophthalmology

Date 2019 Nov 28

PMID 31772766

Citations 2

Authors

Samir M El-Baha

Ahmed M Abdel Hadi

Mahmoud A Abouhussein

Affiliations

Soon will be listed here.

Abstract

Purpose: In this study, we describe a new surgical technique for the treatment of refractory DME. The technique consists of vitrectomy with ILM peeling with a subretinal injection of ranibizumab.

Methods: This is a prospective interventional noncomparative study including patients with refractory DME. Included patients were subjected to the new surgical technique of pars plana vitrectomy with subretinal injection of ranibizumab.

Results: The study included 19 eyes with refractory macular edema, in which this novel technique was attempted. There were 10 males and 9 females. The age of the patients ranged from 17 to 67 years with a mean of 55.58 ± 13.242 years. The duration of diabetes before enrollment in the study ranged from 7 to 25 years with a mean of 16.3 years. Preoperatively, the mean CMT of the eyes ranged from 352 to 883 microns with mean ± SD of 498.58 ± 152.16 microns. Postoperatively, this improved significantly to 373.5 ± 100.3, 355.9 ± 89.8, and 365.74 ± 120.12 microns at 1, 3, and 6 months, respectively ( ≤ 0.001 for all).

Conclusion: This novel surgical procedure of vitrectomy with ILM peeling with a subretinal injection of ranibizumab is effective in cases of refractory DME. The study has been registered in Contact ClinicalTrials.gov PRS Identifier: NCT03975088.

Citing Articles

Current Treatments for Diabetic Macular Edema.

Tatsumi T Int J Mol Sci. 2023; 24(11).

PMID: 37298544 PMC: 10253534. DOI: 10.3390/ijms24119591.

Vitrectomy in Diabetic Macular Edema:: A Swept-source OCT Angiography Study.

Nawrocka Z, Nawrocki J Ophthalmol Sci. 2022; 2(4):100207.

PMID: 36385773 PMC: 9647227. DOI: 10.1016/j.xops.2022.100207.

References

Bonnin S, Sandali O, Bonnel S, Monin C, El Sanharawi M . VITRECTOMY WITH INTERNAL LIMITING MEMBRANE PEELING FOR TRACTIONAL AND NONTRACTIONAL DIABETIC MACULAR EDEMA: Long-term Results of a Comparative Study. Retina. 2014; 35(5):921-8. DOI: 10.1097/IAE.0000000000000433. View

Bhagat N, Grigorian R, Tutela A, Zarbin M . Diabetic macular edema: pathogenesis and treatment. Surv Ophthalmol. 2009; 54(1):1-32. DOI: 10.1016/j.survophthal.2008.10.001. View

Haller J, Qin H, Apte R, Beck R, Bressler N, Browning D . Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology. 2010; 117(6):1087-1093.e3. PMC: 2911350. DOI: 10.1016/j.ophtha.2009.10.040. View

Sebag J, Buckingham B, Charles M, Reiser K . Biochemical abnormalities in vitreous of humans with proliferative diabetic retinopathy. Arch Ophthalmol. 1992; 110(10):1472-6. DOI: 10.1001/archopht.1992.01080220134035. View

Avery R, Castellarin A, Steinle N, Dhoot D, Pieramici D, See R . Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol. 2014; 98(12):1636-41. PMC: 4251300. DOI: 10.1136/bjophthalmol-2014-305252. View

MACHEMER R . Macular translocation. Am J Ophthalmol. 1998; 125(5):698-700. DOI: 10.1016/s0002-9394(98)00020-8. View

Peng Y, Tang L, Zhou Y . Subretinal Injection: A Review on the Novel Route of Therapeutic Delivery for Vitreoretinal Diseases. Ophthalmic Res. 2017; 58(4):217-226. DOI: 10.1159/000479157. View

Doi N, Sakamoto T, Sonoda Y, Yasuda M, Yonemoto K, Arimura N . Comparative study of vitrectomy versus intravitreous triamcinolone for diabetic macular edema on randomized paired-eyes. Graefes Arch Clin Exp Ophthalmol. 2011; 250(1):71-8. DOI: 10.1007/s00417-011-1777-7. View

Ternant D, Paintaud G . Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin Biol Ther. 2005; 5 Suppl 1:S37-47. DOI: 10.1517/14712598.5.1.s37. View

10.

Tachi N, Ogino N . Vitrectomy for diffuse macular edema in cases of diabetic retinopathy. Am J Ophthalmol. 1996; 122(2):258-60. DOI: 10.1016/s0002-9394(14)72018-5. View

11.

Song S, Sohn J, Park K . Evaluation of the efficacy of vitrectomy for persistent diabetic macular edema and associated factors predicting outcome. Korean J Ophthalmol. 2007; 21(3):146-50. PMC: 2629671. DOI: 10.3341/kjo.2007.21.3.146. View

12.

Yanyali A, Horozoglu F, Celik E, Nohutcu A . Long-term outcomes of pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema. Retina. 2007; 27(5):557-66. DOI: 10.1097/01.iae.0000249390.61854.d5. View

13.

Yamamoto T, Hitani K, Tsukahara I, Yamamoto S, Kawasaki R, Yamashita H . Early postoperative retinal thickness changes and complications after vitrectomy for diabetic macular edema. Am J Ophthalmol. 2002; 135(1):14-9. DOI: 10.1016/s0002-9394(02)01819-6. View

14.

Funatsu H, Yamashita H, Ikeda T, Mimura T, Shimizu E, Hori S . Relation of diabetic macular edema to cytokines and posterior vitreous detachment. Am J Ophthalmol. 2003; 135(3):321-7. DOI: 10.1016/s0002-9394(02)01971-2. View

15.

Smiddy W . Economic considerations of macular edema therapies. Ophthalmology. 2011; 118(9):1827-33. PMC: 3483086. DOI: 10.1016/j.ophtha.2010.12.034. View

16.

Elman M, Bressler N, Qin H, Beck R, Ferris 3rd F, Friedman S . Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011; 118(4):609-14. PMC: 3096445. DOI: 10.1016/j.ophtha.2010.12.033. View

17.

Hillenkamp J, Surguch V, Framme C, Gabel V, Sachs H . Management of submacular hemorrhage with intravitreal versus subretinal injection of recombinant tissue plasminogen activator. Graefes Arch Clin Exp Ophthalmol. 2009; 248(1):5-11. DOI: 10.1007/s00417-009-1158-7. View

18.

Nguyen Q, Brown D, Marcus D, Boyer D, Patel S, Feiner L . Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012; 119(4):789-801. DOI: 10.1016/j.ophtha.2011.12.039. View

19.

Stolba U, Binder S, Gruber D, Krebs I, Aggermann T, Neumaier B . Vitrectomy for persistent diffuse diabetic macular edema. Am J Ophthalmol. 2005; 140(2):295-301. DOI: 10.1016/j.ajo.2005.03.045. View

20.

Brown D, Nguyen Q, Marcus D, Boyer D, Patel S, Feiner L . Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013; 120(10):2013-22. DOI: 10.1016/j.ophtha.2013.02.034. View